Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023

Retrieved on: 
Thursday, October 19, 2023
Medical Supplies, Health, Medical Devices, Hospitals, Health Technology, Other Health, Biotechnology, Cerus Corporation, CERS, Webcast, Corporation, Cryptocurrency, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through November 16, 2023.

Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, General Health, Other Health, Health, Health Technology, HR, CHRO, Corporation, Acquisition, Cerus Corporation, CERS, Novartis, Management, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO).

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO).
  • Ms. Goodman will also serve as a member of the Company’s Executive Leadership Team.
  • “We are excited to welcome Alicia to the Cerus team,” said William “Obi” Greenman, Cerus’ president and chief executive officer.
  • “I am excited to be joining the Cerus team at this point in the Company’s remarkable journey to improve blood safety and availability,” said Ms. Goodman.

Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023

Retrieved on: 
Wednesday, July 19, 2023
Health, Hospitals, General Health, Research, Science, Biotechnology, Webcast, Corporation, Cerus Corporation, CERS, Cryptocurrency, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through August 16, 2023.

Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Hospitals, Health, Health Technology, Medical Supplies, Webcast, Corporation, Cerus Corporation, CERS, Cryptocurrency, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through May 18, 2023.

Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

Retrieved on: 
Wednesday, February 15, 2023
Biotechnology, General Health, Medical Devices, Health, Medical Supplies, Cerus Corporation, CERS, Corporation, Webcast, Cryptocurrency, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through March 14, 2023.

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Health, Medical Supplies, Corporation, Growth, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), Uncertainty, Parity, CERS, Pharmaceutical industry, Video game

Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for full-year 2023.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for full-year 2023.
  • Cerus’ unaudited preliminary product revenue for the fourth quarter of 2022 totaled $44.0 million, representing an increase of 10% over the $39.9 million recognized during the fourth quarter of 2021.
  • The Company expects its unaudited preliminary full-year 2022 product revenue to be $162.0 million, which would be at the top end of the Company’s 2022 product revenue guidance range of $160-$162 million and reflect year-over-year growth of 24%.
  • Cerus will provide complete fourth quarter and full-year 2022 financial results and host a call to discuss both 2022 results and 2023 expectations in late February.

Cerus Corporation to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, November 4, 2022
Biotechnology, Health, Clinical Trials, Medical Devices, Corporation, Hospital, FDA, Conference, Bleeding, Cryoprecipitate, Nasdaq, Plasma, CERS, Lotte New York Palace Hotel, EST, Patient, Factor, Pharmaceutical industry, Hotel, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus chief operating officer, is scheduled to participate in two conferences:

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus chief operating officer, is scheduled to participate in two conferences:
    The Stifel 2022 Healthcare Conference on Wednesday, November 16th at 1:50 p.m. EST, at the Lotte New York Palace Hotel.
  • To listen to webcasts of these presentations, please visit the investor relations section of Cerus website at: ir.cerus.com.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Defense, Pharmaceutical, Medical Supplies, Contracts, General Health, Health, FDA, Cryoprecipitate, CERS, Survival, Plasma, Blood transfusion, Food and Drug Administration, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Hospital, Bleeding, Nasdaq, Program, CE, Technology, United States Department of Defense, Factor, Temperature, Trauma, FDA, Patient, Death, Military personnel, Corporation, IBAS, Pharmaceutical industry, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Optimizing survival and recovery of military personnel with combat-related injury is a priority for the Armys Combat Casualty Care Research Program.

Key Points: 
  • Optimizing survival and recovery of military personnel with combat-related injury is a priority for the Armys Combat Casualty Care Research Program.
  • For civilians, trauma with massive bleeding is the leading cause of death for people under the age of 45 years in the U.S.
  • Since 2019, Cerus has been working to develop a lyophilized, pathogen reduced cryoprecipitate product and has advanced this program through several important development milestones, including product feasibility.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.

Cerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day Storage

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Medical Devices, Hospitals, Health, Medical Supplies, Cryoprecipitate, CERS, Plasma, Health, Time, Hospital, Bleeding, Blood, Nasdaq, CE, Platelet, Collection, Adoption, Health Canada, B cell, Transfusion medicine, Factor, FDA, CBS, Patient, Corporation, Pharmaceutical industry, Medical device, Blood product, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), Canadian Blood Services

Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.
  • We look forward to working with Canadian Blood Services to realize these benefits for patients in Canada, Ms. Moore concluded.
  • The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
Thursday, October 20, 2022
Medical Supplies, Medical Devices, Health, General Health, Cardiology, Biotechnology, Bleeding, LinkedIn, Webcast, Investor relations, Patient, Hospital, Nasdaq, Company, Cryoprecipitate, Factor, Corporation, CE, Plasma, FDA, CERS, Online shopping, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Companys financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.